



Cardiac Safety Research Consortium
www.cardiac-safety.org

CSRC COPD Initiative Think Tank Round Table Meeting

March 6, 2014

CSRC COPD Initiative:

A unique Patient Population

- There is a widely accepted link between COPD and Cardiovascular Diseases due to both diseases share common risk factors

A unique Drug Class: Broncodilatators

- With potential direct and indirect Cardiovascular effects
- Most broncodilatators are Inhaled and Long acting compounds



CSRC COPD Initiative: Unmet Needs

- How to characterize those direct and indirect Cardio Vascular effects (shall we be pleased with HR, BP, Cardiac Arrhythmias ...)
- How to collect Cardio Vascular data Phase 2 and Phase 3
- Need of consistent Cardio Vascular Safety data suitable for pooling



CSRC COPD Initiative

Session 1: What is Specific in COPD Population

Session 2: How to characterize CV Effects?

Session 3: How to collect CV data during development

Conclusions – Remarks

Can we agree on a reasonable standard approach?

